Immunoglobulins Market Forecast and Opportunity Assessment till 2026
The Immunoglobulins Market is segmented by Product (IgG, IgA, IgM, IgE, IgD), Mode of Delivery (Intravenous, Subcutaneous), Application (Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP), Immunodeficiency Disease, Myasthenia Gravis, Others) and Region (North America, Europe, Asia-Pacific, and the Rest of the World).
Market Dynamics
The rise in the geriatric population & the number of hemophilic patients improved immunoglobulin production due to the emergence of advanced technologies, and enhanced purification techniques, with better plasma yield, are some of the key factors bolstering the market growth. Also, the surge in prevalence of diseases such as chronic inflammatory demyelinating polyneuropathy (CIDP), hypogammaglobulinemia & others is likely to augment the industry growth. However, stringent government regulations about immunoglobulin products and the high risk of side effects due to the usage of immunoglobulin are anticipated to hinder the market growth.
Regional Analysis
The market in North America accounted for the largest share in 2020 and is projected to continue its dominance during the review period. This is mainly attributed to increasing healthcare expenditure, the growing inclination of clinicians towards immunodeficiency therapies, and the rising level of consciousness for the products involved in the treatment of immunodeficiency disorders. Moreover, beneficial government initiatives and a rise in the number of research partnerships further proliferate regional growth.
COVID-19 Impact
The COVID-19 outbreak positively influenced the growth of the Immunoglobulins market. The growing use of immunoglobulin in the treatment of COVID-19 infection can be effective in the management of the disease. In the US, the impact of COVID-19 on the immunoglobulin market is robust as there have been increasing research studies on immunoglobulins as an effective therapy in the treatment of COVID-19. For instance, as per the National Clinical Trial (NCT) Registry, as of 9th March 2021, in the US, there was around 50 immunoglobulin based ongoing clinical trials across different phases of development which shows a positive impact on the market as this can result to the development of new effective therapy for COVID-19 in the coming years.
Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at sales@stratviewresearch.com.
English
Arabic
Français
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian